Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 27-34 , May 2009

Alternative Indications for Bisphosphonate Therapy

  • Regina Landesberg, DMD, PhD

      Affiliations

    • Associate Professor, Division of Oral and Maxillofacial Surgery, University of Connecticut Health Center, School of Dental Medicine, Farmington, CT. New York Presbyterian Hospital, New York, NY
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Landesberg: Division of Oral and Maxillofacial Surgery, University of Connecticut Health Center, 263 Farmington Ave, L-7056, Farmington, CT 06032
    • ,
  • Sidney Eisig, DDS

      Affiliations

    • George Gutmann Professor of Clinical Craniofacial Surgery and Chairman, Division of Oral Surgery, Columbia University College of Dental Medicine, New York, NY
    • ,
  • Ilene Fennoy, MD

      Affiliations

    • Clinical Professor of Pediatrics–Endocrinology, Medical Director, Comprehensive Adolescent Bariatric Surgery Program, Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY
    • ,
  • Ethel Siris, MD

      Affiliations

    • Madeline C. Stabile Professor of Clinical Medicine, Director, Stabile Osteoporosis Center, Columbia University Medical Center, New York, NY

References 

  1. Neville BW, Damm DD, Allen CM, et al. Oral and Maxillofacial Pathology. In: (ed 3). Philadelphia, PA: WB Sauders; 2008;
  2. Regezi JA, Sciubba J, Jordan R. Oral Pathology: Clinical Pathologic Correlations. In: (ed 5). Philadelphia, PA: WB Saunders; 2007;
  3. Sapp JP, Eversole LR, Wysocki GP. Contemporary Oral and Maxillofacial Pathology. In: (ed 2). St Louis, MO: Mosby; 2003;
  4. Kaugars GE, Niamtu J, Svirsky JA. Cherubism: Diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors. Oral Surg Oral Med Oral Pathol. 1992;73:369
  5. Auclair PL, Cuenin P, Kratochvil FJ, et al. A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor. Oral Surg Oral Med Oral Pathol. 1988;66:197
  6. O'Malley M, Pogrel MA, Stewart JC, et al. Central giant cell granulomas of the jaws: Phenotype and proliferation-associated markers. J Oral Pathol Med. 1997;26:159
  7. Sezer B, Koyuncu B, Gomel M, et al. Intralesional corticosteroid injection for central giant cell granuloma: A case report and review of the literature. Turk J Pediatr. 2005;47:75
  8. Harris M. Central giant cell granulomas of the jaws regress with calcitonin therapy. Br J Oral Maxillofac Surg. 1993;31:89
  9. de Lange J, Rosenberg AJ, van den Akker HP, et al. Treatment of central giant cell granuloma of the jaw with calcitonin. Int J Oral Maxillofac Surg. 1999;28:372
  10. Pogrel MA. Calcitonin therapy for central giant cell granuloma. J Oral Maxillofac Surg. 2003;61:649
  11. Pogrel MA. Discussion: Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg. 2007;65:2024
  12. Kaban LB, Mulliken JB, Ezekowitz RA, et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics. 1999;103(6 Pt 1):1145
  13. Kaban LB, Troulis MJ, Ebb D, et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg. 2002;60:1103
  14. Kaban LB, Dodson TB. Management of giant cell lesions. Int J Oral Maxillofac Surg. 2006;35:1074
  15. Kaban LB, Troulis MJ, Wilkinson MS, et al. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg. 2007;65:2018
  16. Goldman KE, Marshall MK, Alessandrini E, et al. Complications of alpha-interferon therapy for aggressive central giant cell lesion of the maxilla. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;100:285
  17. Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: Treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134:969
  18. Tse LF, Wong KC, Kumta SM, et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study. Bone. 2008;42:68
  19. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101
  20. Vallo A, Rodriguez-Leyva F, Rodriguez SJ. Osteogenesis imperfecta: Anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr. 2006;95:332
  21. Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: Translation of mutation to phenotype. J Med Genet. 1991;28:433
  22. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: A new form of brittle bone disease. J Bone Miner Res. 2000;15:1650
  23. Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: A form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17:30
  24. Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: An autosomal recessive form of brittle bone disease. Bone. 2002;31:12
  25. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947
  26. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res. 2006;12:6222s
  27. Russell RG. Bisphosphonates: Mode of action and pharmacology. Pediatrics. 2007;119(suppl 2):S150
  28. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209
  29. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363
  30. Rauch F. The growing skeleton is a busy place—Can biochemical bone markers keep track of the action?. J Pediatr. 2008;153:454
  31. Andiran N, Alikasifoglu A, Gonc N, et al. Cyclic pamidronate therapy in children with osteogenesis imperfecta: Results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab. 2008;21:63
  32. Cabral de Menezes Filho H, Rodrigues JM, Radonsky V, et al. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta. Horm Res. 2007;68(suppl 5):207
  33. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006;21:132
  34. DiMeglio LA, Ford L, McClintock C, et al. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2005;18:43
  35. Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol. 2005;35:511
  36. Land C, Rauch F, Montpetit K, et al. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr. 2006;148:456
  37. Land C, Rauch F, Travers R, et al. Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment. Bone. 2007;40:638
  38. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977
  39. Lowing K, Astrom E, Oscarsson KA, et al. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr. 2007;96:1180
  40. Munns CF, Rauch F, Travers R, et al. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res. 2005;20:1235
  41. Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779
  42. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846
  43. Poyrazoglu S, Gunoz H, Darendeliler F, et al. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop. 2008;28:483
  44. Rauch F, Munns C, Land C, et al. Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. J Clin Endocrinol Metab. 2006;91:1268
  45. Senthilnathan S, Walker E, Bishop NJ. Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child. 2008;93:398
  46. Zeitlin L, Rauch F, Travers R, et al. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V. Bone. 2006;38:13
  47. Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatr. 2007;119(suppl 2):S163
  48. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr. 1997;131:622
  49. Land C, Rauch F, Munns CF, et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone. 2006;39:901
  50. Kamoun-Goldrat A, Ginisty D, Le MM. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci. 2008;116:195
  51. Rauch F, Travers R, Munns C, et al. Sclerotic metaphyseal lines in a child treated with pamidronate: Histomorphometric analysis. J Bone Miner Res. 2004;19:1191
  52. Damiani D. Metaphyseal sclerosis associated with bisphosphonate therapy. J Pediatr Endocrinol Metab. 2007;20:1167
  53. Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res. 2006;21:374
  54. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;37:196
  55. Schwartz S, Joseph C, Iera D, et al. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: A case series. J Can Dent Assoc. 2008;74:537
  56. McCarthy EA, Raggio CL, Hossack MD, et al. Alendronate treatment for infants with osteogenesis imperfecta: Demonstration of efficacy in a mouse model. Pediatr Res. 2002;52:660
  57. Unal E, Abaci A, Bober E, et al. Oral alendronate in osteogenesis imperfecta. Indian Pediatr. 2005;42:1158
  58. Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25:786
  59. Vyskocil V, Pikner R, Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine. 2005;72:416
  60. Cho TJ, Choi IH, Chung CY, et al. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25:607
  61. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab. 2005;90:405
  62. Madenci E, Yilmaz K, Yilmaz M, et al. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol. 2006;12:53
  63. Akcay T, Turan S, Guran T, et al. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr. 2008;45:105
  64. Chevrel G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: A 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21:300
  65. Shah I, Johari A. Oral bisphosphonate treatment for osteogenesis imperfecta—An Indian perspective. Ann Trop Paediatr. 2007;27:39
  66. Chapurlat RD, Meunier PJ. Fibrous dysplasia of bone. Baillieres Best Pract Res Clin Rheumatol. 2000;14:385
  67. Stephenson RB, London MD, Hankin FM, et al. Fibrous dysplasia (An analysis of options for treatment). J Bone Joint Surg Am. 1987;69:400;1987
  68. Yamamoto T. Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome. J Bone Miner Metab. 2006;24:7
  69. Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22:55
  70. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006;21(suppl 2):P114
  71. Chapurlat RD, Delmas PD, Liens D, et al. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997;12:1746
  72. Chapurlat RD, Hugueny P, Delmas PD, et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment. Bone. 2004;35:235
  73. Parisi MS, Oliveri B, Mautalen CA. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone. 2003;33:582
  74. Lane JM, Khan SN, O'Connor WJ, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res. 2001;382:6
  75. Hempel JM, Karkos PD, Issing WJ. Fibrous dysplasia of the frontal bone. Ear Nose Throat J. 2006;85:654
  76. Bembi B, Deegan P. Gaucher disease: Improving management. Acta Paediatr Suppl. 2008;97:81
  77. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: A review. Br J Radiol. 2002;75(suppl 1):A2
  78. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 2004;104:1253
  79. Harinck HI, Bijvoet OL, van der Meer JW, et al. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet. 1984;8401:513
  80. Ciana G, Cuttini M, Bembi B. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med. 1997;337:712
  81. Samuel R, Katz K, Papapoulos SE, et al. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics. 1994;94:385
  82. Giedion A, Holthusen W, Masel LF, et al. Subacute and chronic “symmetrical” osteomyelitis. Ann Radiol (Paris). 1992;15:329
  83. Carr AJ, Cole WG, Roberton DM, et al. Chronic multifocal osteomyelitis. J Bone Joint Surg Br. 1993;75:582
  84. Gamble JG, Rinsky LA. Chronic recurrent multifocal osteomyelitis: A distinct clinical entity. J Pediatr Orthop. 1984;6:579
  85. Chun CS. Chronic recurrent multifocal osteomyelitis of the spine and mandible: Case report and review of the literature. Pediatrics. 2004;113:e380
  86. Beretta-Piccoli BC, Sauvain MJ, Gal I, et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: A report of ten cases and review of the literature. Eur J Pediatr. 2000;159:594
  87. Suei Y, Tanimoto K, Taguchi A, et al. Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis (One entity or two). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80:401
  88. Simm PJ, Allen RC, Zacharin MR. Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis. J Pediatr. 2008;152:571
  89. Gleeson H, Wiltshire E, Briody J, et al. Childhood chronic recurrent multifocal osteomyelitis: Pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol. 2008;35:707
  90. Compeyrot-Lacassagne S, Rosenberg AM, Babyn P, et al. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol. 2007;34:1585
  91. Yamazaki Y, Satoh C, Ishikawa M, et al. Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:67
  92. Montonen M, Kalso E, Pylkkären L, et al. Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible. Int J Oral Maxillofac Surg. 2001;30:313
  93. Jacobs JJ, Hallab NJ, Urban RM, et al. Wear particles. J Bone Joint Surg Am. 2006;88(suppl 2):99
  94. Hirakawa K, Jacobs JJ, Urban R, et al. Mechanisms of failure of total hip replacements: Lessons learned from retrieval studies. Clin Orthop Relat Res. 2004;420:10
  95. Venesmaa PK, Kröger HP, Miettinen HJ, et al. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study. J Bone Miner Res. 2001;16:2126
  96. Wang CJ, Wang JW, Weng LH, et al. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A:2121
  97. Eberhardt C, Stumpf U, Brankamp J, et al. Osseointegration of cementless implants with different bisphosphonate regimens. Clin Orthop Relat Res. 2006;447:195
  98. Nakamura Y, Hayashi K, Abu-Ali S, et al. Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats. J Bone Joint Surg Am. 2008;90:824
  99. Kurth AH, Eberhardt C, Müller S, et al. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone. 2005;37:204
  100. Wermelin K, Tengvall P, Aspenberg P. Surface-bound bisphosphonates enhance screw fixation in rats—Increasing effect up to 8 weeks after insertion. Acta Orthop. 2007;78:385
  101. Stadelmann VA, Gauthier O, Terrier A, et al. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model (A pilot study). Eur Cell Mater. 2008;16:10
  102. Suratwala SJ, Cho SK, van Raalte JJ, et al. Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am. 2008;90:2189
  103. Wermelin K, Suska F, Tengvall P, et al. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone (Histomorphometry in rats). Bone. 2008;42:365
  104. Iwase M, Kim KJ, Kobayashi Y, et al. A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles. J Orthop Res. 2002;20:499
  105. Astrand J, Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates: High doses are needed in rats. Acta Orthop Scand. 2002;73:24
  106. Tsutsumi R, Hock C, Bechtold CD, et al. Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. J Orthop Res. 2008;26:1340

 This article discusses off-label usage for all of the drugs that are listed. Dr Landesberg has received honoraria from Novartis Pharmaceutical Corporation. Dr Fennoy states no financial arrangements or affiliations with a corporate organization or a manufacturer of products discussed in this article. Dr Siris has received honoraria and paid consulting fees from Novartis, Procter and Gamble, and Sanofi-Aventis.

PII: S0278-2391(08)01834-X

doi: 10.1016/j.joms.2008.12.006

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 27-34 , May 2009

Article Tools

* Image Usage & Resolution